Results 11 to 20 of about 643,840 (294)

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

Lancet, The, 2017
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Aghajanian, C, Aghajanian, Carol, Amit, A, Armstrong, D K, Armstrong, Deborah K, Banerjee, S N, Birrer, M J, Bologna, A, Buck, M, Buss, M K, Cameron, Terri, Chambers, S K, Chen, L-m, Clamp, A, Clamp, Andrew, Coleman, R L, Coleman, Robert L, Colombo, N, Colombo, Nicoletta, Dean, A, Dean, Andrew, Denys, H, Dirix, L, Drew, Y, El-Balat, A, Elit, L, Floquet, A, Floquet, Anne, Fong, P C, Fong, Peter C, Friedlander, M L, Gabra, H G, Gancedo, M Amenedo, Gancedo, Margarita Amenedo, Garcia-Donas, J, Garcia-Donas, Jesus, Ghatage, P, Giordano, Heidi, Gladieff, L, Goble, Sandra, Goh, J C, Goh, Jeffrey C, Grace, Caroline, Guerra, E M, Harding, Thomas C, Harnett, P, Herraez, A Casado, Holloway, R W, Holloway, Robert W, Hänle, C, Isaacson, Jeff, Jackson, D, Joly, F, Kichenadasse, G, Konecny, G E, Konecny, Gottfried E, Kovel, S, Krabisch, P, Leary, A, Leary, Alexandra, Ledermann, J A, Ledermann, Jonathan A, Leviov, M, Lin, Kevin K, Lortholary, A, Lorusso, D, Lorusso, Domenica, Lotz, J, Ma, L, Maloney, Lara, McNeish, I A, McNeish, Iain A, Medioni, J, Morgan, M A, Morris, R T, Mutch, D G, Neunhöffer, T, O'Donnell, A, O'Malley, D M, O'Malley, David M, Oaknin, A, Oaknin, Ana, Oza, A M, Oza, Amit M, Palacio, I, Parkinson, C, Pignata, S, Plante, M, Powell, M, Provencher, D, Pölcher, M, Raponi, Mitch, Romero, I, Sabbatini, R F, Safra, T, Sanchez, A, Scambia, G, Scambia, Giovanni, Scott, C L, Scott, Clare L, Shapira-Frommer, R, Slomovitz, B M, Stemmer, S, Sun, James, Swisher, E M, Swisher, Elizabeth M, Tamberi, S, Tredan, O, Vanderkwaak, T, Vergote, I, Vulfovich, M, Weberpals, J I, Weberpals, Johanne I, Welch, S, Wimberger, P, You, B, Zamagni, C   +116 more
core   +3 more sources

Identifying placebo responders and predictors of response in osteoarthritis: a protocol for individual patient data meta-analysis [PDF]

Systematic Reviews, 2016
Background The management of osteoarthritis (OA) is unsatisfactory, as most treatments are not clinically effective over placebo and most drugs have considerable side effects. On average, 75 % of the analgesic effect from OA treatments in clinical trials
Yu Fu, Monica S. M. Persson, Archan Bhattacharya, Siew-Li Goh, Joanne Stocks, Marienke van Middelkoop, Sita M. A. Bierma-Zeinstra, David Walsh, Michael Doherty, Weiya Zhang   +9 more
doaj   +9 more sources

To respond or not to respond: exploring empathy-related psychological and structural brain differences between placebo analgesia responders and non-responders

Frontiers in Psychology, 2023
IntroductionPlacebo responsiveness is highly variable across individuals. In the domain of pain, it may range from pronounced hypoalgesia to no response at all.
Helena Hartmann, Helena Hartmann, Magdalena Banwinkler, Magdalena Banwinkler, Federica Riva, Claus Lamm   +5 more
doaj   +1 more source

European Headache Federation recommendations for placebo and nocebo terminology

The Journal of Headache and Pain, 2020
Background and aim Despite recent publications, practitioners remain unfamiliar with the current terminology related to the placebo and nocebo phenomena observed in clinical trials and practice, nor with the factors that modulate them.
Dimos D. Mitsikostas, Charlotte Blease, Elisa Carlino, Luana Colloca, Andrew L. Geers, Jeremy Howick, Andrea W. M. Evers, Magne A. Flaten, John M. Kelley, Irving Kirsch, Regine Klinger, Antoinette MaassenVanDenBrink, Daniel E. Moerman, Petros P. Sfikakis, Lene Vase, Tor D. Wager, Fabrizio Benedetti, on behalf of the European Headache Federation   +17 more
doaj   +1 more source

Placebo Effects on Stress, but Not on Pain Reports. A Multi-Experiment Study

Frontiers in Psychology, 2021
BackgroundContextual factors, such as participant/experimenter sex may moderate the placebo effects. We tested whether the participant and experimenter sex modulated placebo effects on experimentally induced pain and associated stress.ObjectiveTo ...
Sara Magelssen Vambheim, Hojjat Daniali, Magne Arve Flaten   +2 more
doaj   +1 more source

Frontal alpha asymmetry: A potential biomarker of approach-withdrawal motivation towards pain

Frontiers in Pain Research, 2022
Pain-related catastrophising is a maladaptive coping strategy known to have a strong influence on clinical pain outcomes and treatment efficacy. Notwithstanding, little is known about its neurophysiological correlates.
Bárbara Silva-Passadouro, Bárbara Silva-Passadouro, Ariane Delgado-Sanchez, James Henshaw, Karen Lopez-Diaz, Nelson J. Trujillo-Barreto, Anthony K. P. Jones, Manoj Sivan, Manoj Sivan   +8 more
doaj   +1 more source

On the Relationship Between Pain Variability and Relief in Randomized Clinical Trials

Frontiers in Pain Research, 2022
Previous research reports suggest greater baseline variability is associated with greater pain relief in those who receive a placebo. However, studies that evidence this association do not control for confounding effects from regression to the mean and ...
Siddharth R. Tiwari, Siddharth R. Tiwari, Andrew D. Vigotsky, Andrew D. Vigotsky, A. Vania Apkarian, A. Vania Apkarian   +5 more
doaj   +1 more source

Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue [PDF]

, 2012
In a recent paper, Horder and colleagues (Horder et al., 2010, J Psychopharmacol 25: 1277–1288) have suggested that the mainproblem in the Kirsch analysis is methodological. We argue that the results are similar irrespective of the method used.
Bech P, Fountoulakis KN, Hans-Jürgen Möller, Kirsch I, Kirsch I, Kirsch I, Konarski JZ, Konstantinos N Fountoulakis, Moncrieff J   +8 more
core   +1 more source

Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. [PDF]

, 2013
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD).
Bogdanov, MB, Boyle, SH, Churchill, E, Delnomdedieu, M, Fiehn, O, Kaddurah-Daouk, R, Krishnan, RR, Pickering, E, Rush, AJ, Wang, Z, Wikoff, WR, Zhu, H   +11 more
core   +2 more sources

Neural Predictors of the Antidepressant Placebo Response

Pharmaceuticals, 2019
The antidepressant placebo response remains a barrier to the development of novel therapies for depression, despite decades of efforts to identify and methodologically address its clinical correlates.
Danielle Rette, Erin McDonald, Dan V. Iosifescu, Katherine A. Collins   +3 more
doaj   +1 more source